Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046423 · ClinicalTrials.gov registry record · Phase 1
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
A Phase 1 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00046423 is a Phase 1 study that has completed, run by Celgene Corporation. The registered enrollment target is 20 participants.
The verdict
NCT00046423, a Phase 1 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.
Interventions
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2000-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046423
The ClinicalTrials.gov registry entry for NCT00046423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABI-007 is the first listed.
NCT00046423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046423 about?
NCT00046423 is a clinical study titled "A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies". This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Tr...
What is the current status of trial NCT00046423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2000-04.
What interventions are being tested in trial NCT00046423?
The interventions under investigation include: ABI-007 (DRUG).
Who is sponsoring clinical trial NCT00046423?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.